Sai Life Sciences Ltd. · NSE:SAILIFE
Sai Life Sciences — Q1 FY27 Earnings Presentation
31 slides from Sai Life Sciences's earnings presentation, Aug 7, 2026
Slide 1: Exchange filing cover letter
07 August 2026 To To National Stock Exchange of India Limited BSE Limited Exchange Plaza, C-1, Block G, Bandra Kurla Phiroze Jeejeebhoy Towers, Dalal Street Complex, Bandra (E), Mumbai – 400 051 Mumbai – 400001 NSE Scrip Symbol: SaiLife BSE Scrip Code: 544306 Sub: Investor Presentation for the quart
Slide 2: Sai Life Sciences Investor Presentation
Sai Life Sciences Investor Presentation August 07, 2026 All rights reserved © 2026 Sai Life Sciences Limited 1 All rights reserved © 2026 Sai Life Sciences Limited
Slide 3: Safe Harbour
Safe Harbour Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "
Slide 4: Message from Mr. Krishna Kanumuri, MD & CEO
We are pleased with the progress made during the quarter and the momentum we continue to see across the business. There is a clear evolution in what large pharmaceutical companies are looking for from their outsourcing partners. The expectation is for strong, scientifically led partners who can take
Slide 5: Message from Mr. Siva Chittor, CFO
We have begun FY27 on a healthy note, delivering revenue of ₹554 crore in Q1, up 12% year-on-year, with growth across both our CRO and CDMO businesses. CRO maintained strong momentum, growing 24% year-on-year, while our CMC pipeline continues to strengthen with 33 active commercial molecules and 14
Slide 6: Executive Summary
“ Sai Make it better together Executive Summary
Slide 7: Q1FY27 Quarterly Snapshot
Q1FY27 Quarterly Snapshot ₹ 554 Cr ₹ 409 Cr ₹ 148 Cr ₹ 73 Cr Revenue Material Margin EBITDA PAT 12% YoY 15% YoY 18% YoY 22% YoY 60 % 40 % 65 % ₹ 263 Cr CDMO Revenue Mix CRO Revenue Mix Capacity Utilization Capex Incurred 6
Slide 8: Consolidated Financial Highlights
Consolidated Financial Highlights Revenue (₹Cr) Material Margin (₹Cr) & Margin (%) EBITDA* (₹Cr) & Margin (%) PAT (₹Cr) & Margin (%) 74% 12% 13% 554 72% 27% 25% 496 409 355 148 125 60 73 Q1FY26 Q1FY27 Q1FY26 Q1FY27 Q1FY26 Q1FY27 Q1FY26 Q1FY27 12% 15% 18% 22% YoY Growth YoY Growth YoY Growth YoY Grow
Slide 9: Business Updates
Business Updates Over 90% Pipeline Visibility on FY27 Targets DISCOVERY CMC KEY PRIORITIES AHEAD • Grew by 24% YoY • Production commenced for 3 • Establishing an integrated • Strengthening large pharma of the 4 molecules added to peptide platform spanning collaborations the pipeline last year discov
Slide 10: Other Business Updates
Other Business Updates • Achieved EcoVadis Platinum Rating 2026, placing Sai Life Sciences among the top 1% of companies globally assessed for sustainability performance. • Capex progress largely on schedule • Operationalized a new 100,000 sq. ft. R&D facility at Genome Valley, Hyderabad • Successfu
Slide 11: Company Overview
“ Sai Make it better together Company Overview
Slide 12: Sai Life Sciences: At a Glance
Sai Life Sciences: At a Glance Integrated CRDMO Outsourcing Offer complete Contract Research, partner to services from Development and pharma drug discovery to Manufacturing innovators manufacturing Organization 27 Years Global Partner Expansive Innovation-Led of Expertise of Choice Infrastructure G
Slide 13: Key Highlights
Key Highlights Fastest growing NSE/BSE 3,800+ 300+ Indian CRDMO Listed on the Indian Total employees Active customers across Stock Exchanges in US, UK, EU, Japan over the last 5 years Dec 2024 11+ years 19/25* USFDA, PMDA Diverse Average tenure of large of the largest pharmaceutical pharma relations
Slide 14: Our Growth Journey
Our Growth Journey 1999 - 2008 2009 – 2013 2014 – 2018 2019 – 2023 2024 – Present Founding & CDMO Biology Foray; CDMO Globalization, Scaled-up Increasing Capacity & Early Biotech Foray Pivot Consolidation Integrated CRDMO Strengthening New-Age Modalities • Incorporated in 1999; began as a • First US
Slide 15: Global Presence
Global Presence Research laboratories for discovery and development located near overseas innovation hubs in Greater Global Team Boston, US and Manchester, UK, complemented by large-scale research laboratories and manufacturing facilities in cost competitive locations in India. 3,800+ Bidar, India E
Slide 16: A leading Integrated CRDMO
A leading Integrated CRDMO Sai Life Sciences operates as both a CRO and a CDMO, offering an end-to-end platform for global pharmaceutical and biotech companies Seamless Mid to Tox to early phase supplies late phase supplies Integration One-stop solution Commercial supplies from research to commercia
Slide 17: End-to-end Capabilities, Small Molecule Focus
End-to-end Capabilities, Small Molecule Focus Discovery Development Manufacturing From target ID & validation to IND Stage Complex chemical synthesis from • 700 KL Capacity with manufacturing Blocks through Creative Chemistry, Complex development to commercialization. • 80 Production trains Biology,
Slide 18: Discovery Services spanning Target Validation to IND
Discovery Services spanning the entire journey from Target Validation to IND Integrated services: Synthetic & Medicinal Chemistry, CADD, Biology, DMPK and Toxicology Lead Candidate n Ma sig ke / De Ch Target Evaluation em In vivo Pharmacology istr y Analyze HIT ID Toxicology PK M D y & Test / Bi o l
Slide 19: Discovery Services (CRO)
Discovery Services (CRO) Consistent Revenue Growth (₹ Cr) 775 626 Client Stickiness Automation Modalities Expansion 467 497 274 >65% Revenues from Focus on automation Expanding capabilities customers in FY23-26 and scale in DMPK and in ADCs, TPDs, FY22 FY23 FY24 FY25 FY26 who availed more than biolo
Slide 20: Discovery Services: Scaling Innovation, Driving Impact
Discovery Services: Scaling Innovation, Driving Impact >65% of Discovery programs are now integrated, with active use of next-gen biology, automation, and AI to accelerate development and improve outcomes Expanded Core Colocalized & Tech-Enabled Drug Specialized Next-Gen Capabilities Global Teams Di
Slide 21: Development Services from H2L to Commercial Supply
Development Services from H2L to Commercial Supply Underpinned by integrated scientific approaches applied in a phase-appropriate manner • Continuous Verification • Control • Continuous Strategy Improvement • Process Definition Optimization Lifecycle • API Developability & Design Strategy Commercial
Slide 22: CMC Services (CDMO)
CMC Services (CDMO) • End-to-End capabilities from IND through to commercialization Consistent Revenue Growth (₹ Cr) • Focus on Complex Chemistry, ADC Payloads & Linkers • Modern, GMP-compliant facilities across UK and India 1,417 • Flexibility to support both small-scale clinical supplies and large
Slide 23: New Modalities: Fortifying foundation to build scale
New Modalities: Fortifying foundation to build scale Peptides Antibody-Drug Conjugates Complement peptide discovery with Enhancing conjugation in Discovery; New Modalities Revenue Contribution (%) upgrading to class 6 containment for process and scale-up facilities for clinical supplies; focus on co
Slide 24: Our Strengths
“ Sai Make it better together Our Strengths
Slide 25: Information Technology-Driven Excellence: Digitization & Beyond
Information Technology - Driven Excellence: Digitization & Beyond Digitization Digitalization Digital Transformation 2017 onwards 2022 onwards 2023 onwards Converting data, documents and processes Use of digitized data for effective monitoring integration of digital technologies into all from paper/
Slide 26: Global-Standard Operations, End-to-End
Global-Standard Operations, End-to-End Quality Assurance Sustainability Leadership Safety & EHS Leadership • 300+ QA/QC professionals • 100% renewable energy at • Embedded Process Safety from across sites Bidar site quote to execution phase; • Integrated e-systems: LIMS, e- • Zero Liquid Discharge:
Slide 27: Annexure
“ Sai Make it better together Annexure
Slide 28: Consolidated Statement of Profit and Loss
Consolidated Statement of Profit and Loss Particulars (₹ Cr) Q1FY27 Q4FY26 Q1FY26 Revenue from operations 554 602 496 Other income 4 3 6 Total income 558 605 502 Expenses Cost of materials consumed and changes in inventories 145 162 141 Employee benefits expense 180 187 161 Other expenses 80 77 74 F
Slide 29: Awards Certificates & Accreditations
Awards Certificates & Accreditations Member of: Accelerating the Discovery, ISO 14001:2015, ISODevelopment 45001:2018, and Manufacturing of small ISO 50001:2018, ISOmolecules 27001:2022 & ISO 28000:2022 certifications Certificate of Registration: Information Certified for Social Accountability and S
Slide 30: Glossary
Glossary APIs Active pharmaceutical ingredients Biotechnology companies, often referred to as biotech companies, are largely startups in the pharmaceutical sector which typically focus on developing innovative drugs and drug Biotechs development technologies to address unmet medical needs Blockbuste
Slide 31: Thank You
Thank You For more details please contact: Investorrelation@sailife.com © Sai Life Sciences Limited. L4, SLN Terminus, Gachibowli, Hyderabad 500032, Telangana, India.